Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14993926 | 0.86 | TDP1 (0.30) | PGD | |
| SCHEMBL14993927 | 0.86 | TDP1 (0.30) | PGD | |
| SCHEMBL3975207 | 0.82 | — | — | |
| SCHEMBL4808921 | 0.82 | — | — | |
| SCHEMBL1155333 | 0.82 | — | — | |
| SCHEMBL4180699 | 0.81 | PGD (0.33) | PGD | |
| SCHEMBL4180706 | 0.81 | PGD (0.33) | PGD | |
| SCHEMBL4455207 | 0.81 | PGD (0.33) | PGD | |
| SCHEMBL1155343 | 0.80 | PGD (0.30) | PGD | |
| SCHEMBL2636857 | 0.79 | SMN1; SMN2 (0.35) | PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025667-B1 | 9,10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO LTD (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-8796246-B2 | 9, 10-secopregnane derivative and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20100130454-A1 | 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100016263-A1 | 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2025667-A1 | 9,10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1829860-A1 | 9,10-SECOPREGNANE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130454-A1 | 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE | VDR, CYP2R1, CYP24A1 | PGD 2593/4885 |
| US-20100016263-A1 | 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | CYP2R1, VDR, CYP24A1 | PGD 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.